top of page

Wissenschaftliche Studien zu mRNA

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older

Cardiac

Acute Myocarditis Following mRNA COVID-19 Vaccine

Cardiac

Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination

Cardiac

Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose

Cardiac

Acute Myocarditis Following Vaccination With the First Dose of the mRNA-1273 Vaccine

Cardiac

Acute Myocarditis in a Patient Following mRNA-1273 SARS-CoV-2 Vaccination

Cardiac

Acute myocarditis in a young adult two days after Pfizer vaccination

Cardiac

Acute Myopericarditis after COVID-19 Vaccine in Teenagers

Cardiac

Acute Myopericarditis After First Dose of mRNA-1273 SARS-CoV-2 Vaccine in a Young Adult

Cardiac

Acute Myopericarditis after the Second Dose of mRNA COVID-19 Vaccine Mimicking Acute Coronary Syndrome

Cardiac

Acute myopericarditis and left shoulder capsulitis following second dose of mRNA SARS-CoV-2 Moderna vaccination

Cardiac

Acute necrotizing eosinophilic myocarditis after COVID-19 vaccination

Cardiac

Acute pericarditis and cardiac tamponade after Covid-19 vaccination

Cardiac

Acute pericarditis as a major clinical manifestation of long COVID-19 syndrome

Cardiac

Acute Pericarditis Post mRNA-1273 COVID Vaccine Booster

Cardiac

Acute Pericarditis with High Anti-Nuclear Antibody Titers Following BNT162b2 mRNA COVID-19 Vaccination

Cardiac

Acute Perimyocarditis Following First Dose of mRNA Vaccine Against COVID-19

Cardiac

Acute Perimyocarditis in an Adolescent Japanese Male after a Booster Dose of the BNT162b2 COVID-19 Vaccine

Cardiac

Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopaenia

Cardiac

Adverse events following COVID-19 mRNA vaccines, A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia

Cardiac

bottom of page